144 related articles for article (PubMed ID: 35086719)
1. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
Nakauma-González JA; Rijnders M; van Riet J; van der Heijden MS; Voortman J; Cuppen E; Mehra N; van Wilpe S; Oosting SF; Rijstenberg LL; Westgeest HM; Zwarthoff EC; de Wit R; van der Veldt AAM; van de Werken HJG; Lolkema MPJ; Boormans JL
Eur Urol; 2022 Apr; 81(4):331-336. PubMed ID: 35086719
[TBL] [Abstract][Full Text] [Related]
2. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
3. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.
Cox A; Klümper N; Stein J; Sikic D; Breyer J; Bolenz C; Roghmann F; Erben P; Wirtz RM; Wullich B; Ritter M; Hölzel M; Schwamborn K; Horn T; Gschwend J; Hartmann A; Weichert W; Erlmeier F; Eckstein M
Eur Urol; 2024 Apr; 85(4):328-332. PubMed ID: 37031005
[TBL] [Abstract][Full Text] [Related]
4. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
[TBL] [Abstract][Full Text] [Related]
5. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
[TBL] [Abstract][Full Text] [Related]
6. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
7. The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.
Ohara K; Rendeiro AF; Bhinder B; Eng KW; Ravichandran H; Nguyen D; Pisapia D; Vosoughi A; Fernandez E; Shohdy KS; Manohar J; Beg S; Wilkes D; Robinson BD; Khani F; Bareja R; Tagawa ST; Ouseph MM; Sboner A; Elemento O; Faltas BM; Mosquera JM
Nat Commun; 2024 Mar; 15(1):2009. PubMed ID: 38499531
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
9. Re: J. Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol 2022;81:331-6: Novel Insights into Evidence of Metastatic Urothelial Carcinoma Transcriptomic Subtype.
Song Y; Qin C; Xu T
Eur Urol; 2022 Sep; 82(3):e76-e77. PubMed ID: 35715367
[No Abstract] [Full Text] [Related]
10. Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer.
Damrauer JS; Beckabir W; Klomp J; Zhou M; Plimack ER; Galsky MD; Grivas P; Hahn NM; O'Donnell PH; Iyer G; Quinn DI; Vincent BG; Quale DZ; Wobker SE; Hoadley KA; Kim WY; Milowsky MI
Nat Commun; 2022 Nov; 13(1):6658. PubMed ID: 36333289
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
[TBL] [Abstract][Full Text] [Related]
12. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
13. Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
Sjödahl G; Eriksson P; Holmsten K; Abrahamsson J; Höglund M; Bernardo C; Ullén A; Liedberg F
Int J Cancer; 2024 Jan; 154(1):180-190. PubMed ID: 37671617
[TBL] [Abstract][Full Text] [Related]
14. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
[TBL] [Abstract][Full Text] [Related]
15. Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.
Pezzicoli G; Ciciriello F; Musci V; Minei S; Biasi A; Ragno A; Cafforio P; Rizzo M
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674231
[TBL] [Abstract][Full Text] [Related]
16. A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
Patschan O; Sjödahl G; Chebil G; Lövgren K; Lauss M; Gudjonsson S; Kollberg P; Eriksson P; Aine M; Månsson W; Fernö M; Liedberg F; Höglund M
Eur Urol; 2015 Nov; 68(5):824-32; discussion 835-6. PubMed ID: 25770486
[TBL] [Abstract][Full Text] [Related]
17. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
18. Molecular Subtypes of Bladder Cancer: Component Signatures and Potential Value in Clinical Decision-making.
Warrick J
Adv Anat Pathol; 2024 May; 31(3):178-187. PubMed ID: 38231156
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Chen S; Zhang N; Wang T; Zhang E; Wang X; Zheng J
Front Immunol; 2020; 11():1900. PubMed ID: 32983112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
